ExeVir

Executive Summary

ExeVir is a Belgian clinical-stage biotechnology company developing novel antibody therapies for rapidly spreading infectious diseases, leveraging its proprietary platform based on camelid single-domain antibodies (VHH). Founded in 2020 and based in Ghent, the company initially focuses on COVID-19 and dengue, aiming to address unmet medical needs with multi-specific therapeutic constructs. Its modular platform enables rapid generation of potent, broadly neutralizing antibodies with favorable pharmacokinetics and manufacturing scalability. ExeVir has advanced its lead COVID-19 antibody candidate into Phase 1 clinical trials, evaluating safety, tolerability, and pharmacokinetics in healthy volunteers. The company also has a preclinical dengue program targeting all four serotypes. Despite being early-stage, ExeVir's unique VHH technology offers potential advantages over conventional antibodies, including enhanced stability, ease of reformatting, and lower production costs. The company operates in a competitive landscape but its focus on pandemic preparedness and endemic infectious diseases positions it for potential partnerships or public health interest. Key near-term milestones include Phase 1 data readout for its COVID-19 candidate and progression of its dengue program towards clinical development.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 data readout for COVID-19 antibody candidate60% success
• Q2 2027Initiation of Phase 2 trial for COVID-19 antibody50% success
• Q3 2027IND filing for dengue antibody program40% success